Akari Therapeutics, Plc (AKTX) NASDAQ
14.63
+1.2(+8.94%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Akari Therapeutics, Plc
Address
75/76 Wimpole Street
London, FL W1G 9RT
United Kingdom of Great Britain and Northern Ireland (the)
Phone
44 20 8004 0270
Website
Sector
Healthcare
Industry
Biotechnology
Employees
8
First IPO Date
January 06, 2014
Key Executives
| Name | Title | Pay | Year Born |
| Abizer Gaslightwala | Chief Executive Officer, President & Director | 476,149 | 1974 |
| Kameel D. Farag | Interim Chief Financial Officer | 251,493 | 1979 |
| Satyajit Mitra | Executive Director & Head of Oncology | 0 | 1975 |
Description
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
